Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

ABSTRACT:

Introduction

Patients with early-stage breast cancer, treated with endocrine therapy, have approximately 90% 5-year disease-free survival. However, for patients at higher risk of relapse despite endocrine therapy, additional adjuvant therapy, such as chemotherapy, may be indicated. The challenge is to prospectively identify such patients. The Mammostrat® test uses five immunohistochemical markers to stratify patients on tamoxifen therapy into risk groups to inform treatment decisions. We tested the efficacy of this panel in a mixed population of cases treated in a single center with breast-conserving surgery and long-term follow-up.

Methods

Tissue microarrays from a consecutive series (1981 to 1998) of 1,812 women managed by wide local excision and postoperative radiotherapy

SUBMITTER: Bartlett JM 

PROVIDER: S-EPMC2949634 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature